tetano
Editor, Senior Moderator
Nat Commun
. 2020 Nov 30;11(1):6121.
doi: 10.1038/s41467-020-19819-1.
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
Flavia Chiuppesi[SUP] 1 [/SUP], Marcela d'Alincourt Salazar[SUP] 1 [/SUP], Heidi Contreras[SUP] 1 [/SUP], Vu H Nguyen[SUP] 1 [/SUP], Joy Martinez[SUP] 1 [/SUP], Yoonsuh Park[SUP] 1 [/SUP], Jenny Nguyen[SUP] 1 [/SUP], Mindy Kha[SUP] 1 [/SUP], Angelina Iniguez[SUP] 1 [/SUP], Qiao Zhou[SUP] 1 [/SUP], Teodora Kaltcheva[SUP] 1 [/SUP], Roman Levytskyy[SUP] 1 [/SUP], Nancy D Ebelt[SUP] 2 [/SUP], Tae Hyuk Kang[SUP] 3 [/SUP], Xiwei Wu[SUP] 3 [/SUP], Thomas F Rogers[SUP] 4 5 [/SUP], Edwin R Manuel[SUP] 2 [/SUP], Yuriy Shostak[SUP] 6 [/SUP], Don J Diamond[SUP] 7 [/SUP], Felix Wussow[SUP] 8 [/SUP]
Affiliations
Abstract
Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.
. 2020 Nov 30;11(1):6121.
doi: 10.1038/s41467-020-19819-1.
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
Flavia Chiuppesi[SUP] 1 [/SUP], Marcela d'Alincourt Salazar[SUP] 1 [/SUP], Heidi Contreras[SUP] 1 [/SUP], Vu H Nguyen[SUP] 1 [/SUP], Joy Martinez[SUP] 1 [/SUP], Yoonsuh Park[SUP] 1 [/SUP], Jenny Nguyen[SUP] 1 [/SUP], Mindy Kha[SUP] 1 [/SUP], Angelina Iniguez[SUP] 1 [/SUP], Qiao Zhou[SUP] 1 [/SUP], Teodora Kaltcheva[SUP] 1 [/SUP], Roman Levytskyy[SUP] 1 [/SUP], Nancy D Ebelt[SUP] 2 [/SUP], Tae Hyuk Kang[SUP] 3 [/SUP], Xiwei Wu[SUP] 3 [/SUP], Thomas F Rogers[SUP] 4 5 [/SUP], Edwin R Manuel[SUP] 2 [/SUP], Yuriy Shostak[SUP] 6 [/SUP], Don J Diamond[SUP] 7 [/SUP], Felix Wussow[SUP] 8 [/SUP]
Affiliations
- PMID: 33257686
- DOI: 10.1038/s41467-020-19819-1
Abstract
Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.